Subscribe
shutterstock_309001163_bill_perry
Bill Perry / Shutterstock.com
21 January 2021Americas

Federal Circuit agrees with PTAB in optical patent appeal

The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board (PTAB) which centered on the validity of a patent for an ophthalmic illuminator.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.

More on this story

Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?